Calidi Biotherapeutics Inc (CLDI) Stock Price, Quote & News

Company Profile

Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors. It...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 794 9600

Fax: 858 794 9605

Website: www.calidibio.com

Address:

4475 Executive Drive, Suite 200, San Diego, United States

race2zero May. 15 at 11:52 PM

$CLDI @Sabby_Management our newbie to CLDI @NovaFoster came in today and got a dose of truth she doesn’t want to belief and already blocked me. She doesn’t want to hear how bad this is going to end

0 · Reply

race2zero May. 15 at 11:41 PM

$CLDI let’s go! I’m happy with finishing the week in the .17s but would love .16s, 20 mins left, you can do it! Price target for next week .12. 5 consecutive days of all time lows being set on a week they presented at the highest cancer conference of the year! Absolute clowns, 🤡 you can make this up!

0 · Reply

race2zero May. 15 at 8:46 PM

$CLDI @Spy_Guy how’s the new house you bought with CLDI?

1 · Reply

race2zero May. 15 at 8:02 PM

$CLDI come on! Someone step up and take those .24s🤣🤣🤣🤣

0 · Reply

race2zero May. 15 at 7:06 PM

$CLDI voting is already happening and you know as well as I do they always pass. Also, they can adjourn the meeting until they get the votes they need. They themselves said they don’t forget expect an update (catalyst) until end of year at the earliest, they also said they don’t have enough money to operate for another year

1 · Reply

race2zero May. 15 at 6:54 PM

$CLDI welcome! They’ll be out of cash again by EOY. Reverse split upcoming with built in dilution and of course additional dilution they’ll add shortly after that’s done. The deal with Armistice is another death blow to retail holders. Company has no chance at survival. It’s had more volume and more attempts at good news than ever and it sets a new all-time low daily. Eric Poma did this exact same blueprint with his last company, cash his own check and move on

1 · Reply

NovaFoster May. 15 at 6:54 PM

$CLDI Everyone screaming RS like it’s tomorrow. Shareholder vote isn’t even until June 12. Stock’s sitting at .18 on a low float oncology play with active catalysts before any possible RS can even happen. That’s a long time in penny stock land.

0 · Reply

NovaFoster May. 15 at 6:51 PM

$CLDI at .18 while warrants sit at .23 and .25. People panic dumping below levels institutions literally paid for. Low float oncology names can turn violent fast when sentiment flips.

0 · Reply

NovaFoster May. 15 at 6:46 PM

$CLDI Cash position held up way better than expected after the offering and they’re still guiding toward the CLD-401 IND this year. Market keeps pricing these low float oncology names like they’re dead until one headline changes everything. Doesn’t take much volume for these things to wake up fast.

0 · Reply

race2zero May. 15 at 4:42 PM

$CLDI ouch! That’s not good for bulls. Armstice capital is a key player for highly dilutive biotech financings which will more than likely lead to future PIPE deals, warrant heavy raises, convertible structures and ATM usage. It’s basically like a payday loan shop on the corner in the worst part of a city

0 · Reply

Calidi Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Operational Highlights

May 13, 2026, 8:00 AM EDT - 2 days ago

Calidi Biotherapeutics Confirms Featured Speaker Presentation Tomorrow at the ASGCT Conference in Boston

Apr 29, 2026, 8:00 AM EDT - 16 days ago

Calidi Biotherapeutics Announces Strategic Partnership with TransferAI to Drive Efficiencies in the IND Submission Process for CLD-401 Using Agentic AI

2026-04-21T13:29:48.000Z - 24 days ago

Calidi presents new data on CLD-401 at AACR

2026-04-20T12:54:38.000Z - 25 days ago

Calidi presents new data on in situ t-cell engagers at AACR

Apr 20, 2026, 8:00 AM EDT - 25 days ago

Calidi Biotherapeutics Presents New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026

Mar 27, 2026, 4:25 PM EDT - 7 weeks ago

Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational Highlights

2026-03-12T12:17:48.000Z - 2 months ago

Calidi presents manufacturing process for CDI-401 at BioProcessing Summit

Mar 12, 2026, 8:00 AM EDT - 2 months ago

Calidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioprocessing Summit; FDA Feedback Support Company's Approach to Manufacturing

Mar 9, 2026, 8:50 PM EDT - 2 months ago

Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment Option

2026-03-06T13:35:48.000Z - 2 months ago

Calidi prices 10.5M units at 50c in underwritten public offering

Mar 6, 2026, 8:30 AM EST - 2 months ago

Calidi Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public Offering

2026-03-05T23:00:46.000Z - 2 months ago

Calidi announces offering of units, no amount given

Mar 5, 2026, 5:57 PM EST - 2 months ago

Calidi Biotherapeutics Announces Proposed Public Offering

2026-02-20T13:11:19.000Z - 3 months ago

Calidi presents data on novel approach to use of BiTEs

Feb 20, 2026, 8:00 AM EST - 3 months ago

Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO Conference

2026-02-12T13:10:13.000Z - 3 months ago

Calidi to present on approach to bispecific T-cell engagers using RedTail

Feb 12, 2026, 8:00 AM EST - 3 months ago

Calidi Biotherapeutics To Present on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform in a Late-Breaking Abstract at the 2026 AACR-IO Conference

2026-01-28T13:13:01.000Z - 3 months ago

Calidi announces 2026 milestones

Nov 17, 2025, 8:00 AM EST - 6 months ago

Calidi Biotherapeutics Announces Exclusive Live Investor Webinar and Q&A Session on November 19, 2025

Nov 13, 2025, 4:15 PM EST - 6 months ago

Calidi Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Operational Highlights

2025-11-10T13:20:35.000Z - 6 months ago

Calidi presents new data on CLD-401 at 2025 SITC annual meeting

2025-10-30T12:15:32.000Z - 7 months ago

Calidi announces new data to be presented on CLD-401 at 2025 SITC meeting

2025-10-22T12:11:42.000Z - 7 months ago

Calidi announces formation of its Scientific Advisory Board

Aug 21, 2025, 6:33 PM EDT - 9 months ago

Calidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment Option

2025-08-20T13:20:27.000Z - 9 months ago

Calidi prices 1.47M units at $2.00 in underwritten public offering

Aug 20, 2025, 9:15 AM EDT - 9 months ago

Calidi Biotherapeutics Announces Pricing of $6 Million Underwritten Public Offering

Aug 8, 2025, 4:15 PM EDT - 10 months ago

Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights

2025-08-05T13:46:30.000Z - 10 months ago

Calidi Biotherapeutics Inc trading resumes

2025-08-05T13:43:07.000Z - 10 months ago

Calidi Biotherapeutics Inc trading halted, volatility trading pause

2025-07-29T12:22:15.000Z - 10 months ago

Calidi receives FDA Fast Track designation for CLD-201

2025-07-25T20:50:25.000Z - 10 months ago

Calidi announces 1-for-12 reverse stock split

Jul 25, 2025, 4:45 PM EDT - 10 months ago

Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025

Jul 22, 2025, 8:00 AM EDT - 10 months ago

Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on July 24

2025-07-19T02:35:14.000Z - 10 months ago

Calidi files to sell 6.6M shares of common stock for holders

Jul 10, 2025, 8:30 AM EDT - 11 months ago

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Platform Designed to Transform Landscape of Cancer Treatment

Jul 9, 2025, 2:01 PM EDT - 11 months ago

Calidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross Proceeds

Jul 8, 2025, 8:30 AM EDT - 11 months ago

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Developing Precision Genetic Medicine Platform for Cancer Treatment

Jun 27, 2025, 8:00 AM EDT - 11 months ago

Calidi Biotherapeutics Announces Shareholder Letter from CEO

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711

Apr 16, 2025, 9:30 AM EDT - 1 year ago

Global X Offers Precise U.S. Equity Exposure with Launch of Domestic Focused Funds

EGLE

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Calidi Biotherapeutics Announces Closing of $3.9 Million Registered Direct Offering and Concurrent Private Placement

Mar 28, 2025, 9:00 AM EDT - 1 year ago

Calidi Biotherapeutics Announces Pricing of $3.9 Million Registered Direct Offering and Concurrent Private Placement

Mar 10, 2025, 8:00 AM EDT - 1 year ago

Calidi Biotherapeutics Announces Demonstrated Ability To Deliver Transient Gene Therapy (Payload) To Tumors Using Systemic Platform

Feb 28, 2025, 9:00 AM EST - 1 year ago

Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

OSTX

Feb 24, 2025, 8:00 AM EST - 1 year ago

Calidi Biotherapeutics Announces Commencement of Recruitment for Multiple Dose CLD-101 Trial in Patients with Newly Diagnosed High Grade Glioma at Northwestern University Hospital

Jan 29, 2025, 8:00 AM EST - 1 year ago

Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on February 5

Jan 28, 2025, 8:00 AM EST - 1 year ago

Calidi Biotherapeutics Announces Bolstered Cash Balance and Termination of its Standby Equity Purchase Agreement

Jan 10, 2025, 4:30 PM EST - 1 year ago

Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock

Jan 10, 2025, 8:30 AM EST - 1 year ago

Calidi Biotherapeutics Announces Pricing of $4.25 Million Public Offering of Common Stock

Nov 15, 2024, 4:05 PM EST - 1 year ago

Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock

Nov 14, 2024, 8:30 AM EST - 1 year ago

Calidi Biotherapeutics Announces Pricing of $7.5 Million Public Offering of Common Stock

Nov 12, 2024, 5:29 PM EST - 1 year ago

Calidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results

Oct 25, 2024, 9:00 AM EDT - 1 year ago

Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

NXL

Oct 24, 2024, 8:30 AM EDT - 1 year ago

Calidi Biotherapeutics to Present Data Supporting RTNova at Upcoming Scientific Conferences

Oct 23, 2024, 8:31 AM EDT - 1 year ago

Calidi Biotherapeutics Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement

Oct 18, 2024, 11:00 PM EDT - 1 year ago

NYSE American to Commence Delisting Proceedings with Respect to the Warrants of Calidi Biotherapeutics, Inc. (CLDI WS)

Oct 18, 2024, 8:45 AM EDT - 1 year ago

Calidi Biotherapeutics and Gorilla Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

GRRR

Aug 13, 2024, 5:37 PM EDT - 1 year ago

Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results

Aug 2, 2024, 9:00 AM EDT - 1 year ago

GreenPower Motor and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Jul 29, 2024, 9:00 AM EDT - 1 year ago

Calidi Biotherapeutics Announces Launch of Nova Cell Subsidiary and $3 Million Aggregate Investment from Dr. Ronald Rigor

Jul 18, 2024, 8:00 AM EDT - 1 year ago

Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform

Jul 16, 2024, 8:00 AM EDT - 1 year ago

Calidi Biotherapeutics Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board

Jul 5, 2024, 4:15 PM EDT - 2 years ago

Calidi to Effect Reverse Stock Split

race2zero May. 15 at 11:52 PM

0 · Reply

race2zero May. 15 at 11:41 PM

0 · Reply

race2zero May. 15 at 8:46 PM

$CLDI @Spy_Guy how’s the new house you bought with CLDI?

1 · Reply

race2zero May. 15 at 8:02 PM

$CLDI come on! Someone step up and take those .24s🤣🤣🤣🤣

0 · Reply

race2zero May. 15 at 7:06 PM

1 · Reply

race2zero May. 15 at 6:54 PM

1 · Reply

NovaFoster May. 15 at 6:54 PM

0 · Reply

NovaFoster May. 15 at 6:51 PM

$CLDI at .18 while warrants sit at .23 and .25. People panic dumping below levels institutions literally paid for. Low float oncology names can turn violent fast when sentiment flips.

0 · Reply

NovaFoster May. 15 at 6:46 PM

0 · Reply

race2zero May. 15 at 4:42 PM

0 · Reply

Sabby_Management May. 15 at 4:14 PM

$CLDI they got a buyer schedule 13g filed armstice capital.

0 · Reply

race2zero May. 15 at 2:30 PM

$SKLZ if you need your money back come to $CLDI in a month or so and short after the reverse split. It’ll be the easiest money you’ve ever made

0 · Reply

race2zero May. 15 at 2:04 PM

$CLDI will you be joining us to short this into delisting after the reverse split?

1 · Reply

supermanme May. 15 at 1:52 PM

$CLDI good entry point

0 · Reply

uindicator May. 15 at 1:43 PM

$CLDI i guess no one is buying what they’re trying to sell at these conferences

0 · Reply

race2zero May. 15 at 1:39 PM

$CLDI a lot of shares being liquidated in the .16s, not a single one of them in the green. A new all time low at every day this week

0 · Reply

race2zero May. 15 at 1:34 PM

$CLDI 2500s today, it’s a game you can’t win bulls

0 · Reply

race2zero May. 15 at 1:26 PM

$CLDI those 2600 blocks should be in the .15s at open and drift down to at least .14s, maybe .13s as the day moves on

0 · Reply

race2zero May. 15 at 12:48 PM

$CLDI @Spy_Guy and @Drewrr you guys good?

0 · Reply

race2zero May. 15 at 12:45 PM

$CLDI I wonder if Andrew Jackson dumped his massive amount of shares. You should know not to buy a stock where the CFO only owns 2500 shares

1 · Reply

race2zero May. 15 at 12:43 PM

$CLDI good luck dude, come back after the reverse split and short this POS with us and get your money back plus some, it’ll be the easiest money ever

1 · Reply

race2zero May. 15 at 12:31 PM

$CLDI

0 · Reply

Market Cap	2.07M
Revenue (ttm)	0.00
Net Income (ttm)	-19.91M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.16

Volume	3,596,000
Avg Vol	4,855,110
Day's Range	N/A - N/A
Shares Out	10.90M
Stochastic %K	43%
Beta	1.38
Analysts	Strong Buy
Price Target	$10.00